Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2019-05-20 | FTSV | Forty Seven, Inc. | McCamish Mark Anthony | Pres, CEO | S - Sale+OE | $12.10 | -16,500 | 60,719 | -21% | -$199,726 | |||||
2019-05-20 | EOLS | Evolus, Inc. | Romine Kristine | Dir | P - Purchase | $19.25 | +40,562 | 80,909 | +101% | +$780,819 | ||||||
2019-05-20 | EOLS | Evolus, Inc. | Blank Simone | Dir | P - Purchase | $19.25 | +628,536 | 923,560 | +213% | +$12,099,318 | ||||||
2019-05-20 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $13.50 | +50,000 | 15,759,014 | 0% | +$675,000 | ||||||
| DM | 2019-05-20 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $130.07 | -2,500 | 271,621 | -1% | -$325,168 | |||||
2019-05-20 | ADRO | Aduro Biotech, Inc. | Ferber Celeste | SVP, GC, Secretary | S - Sale | $3.21 | -2,000 | 29,436 | -6% | -$6,413 | ||||||
2019-05-20 | NGM | Ngm Biopharmaceuticals Inc | Svennilson Peter | Dir, 10% | P - Purchase | $13.50 | +50,000 | 15,589,014 | 0% | +$675,000 | ||||||
| D | 2019-05-21 | BGNE | Beigene, Ltd. | Liang Howard | CFO, Chief Strategy Officer | S - Sale+OE | $130.21 | -23,200 | 52,338 | -31% | -$3,020,860 | |||||
2019-05-20 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | 10% | P - Purchase | $13.50 | +50,000 | 15,584,014 | 0% | +$675,000 | ||||||
| M | 2019-05-20 | MDCO | Medicines Co /de | Denner Alexander J | Dir | P - Purchase | $33.89 | +431,000 | 4,067,000 | +12% | +$14,606,470 | |||||
2019-05-21 | ARWR | Arrowhead Pharmaceuticals, Inc. | Myszkowski Kenneth Allen | CFO | S - Sale | $22.00 | -27,071 | 278,536 | -9% | -$595,562 | ||||||
2019-05-20 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | P - Purchase | $112.01 | +250 | 116,237 | 0% | +$28,003 | ||||||
2019-05-20 | ADMP | Adamis Pharmaceuticals Corp | Carlo Dennis J Phd | Pres,amp; CEO | S - Sale | $1.73 | -11,184 | 620,999 | -2% | -$19,339 | ||||||
2019-05-20 | ADMP | Adamis Pharmaceuticals Corp | Daniels Karen K. | VP of Operations | S - Sale | $1.73 | -5,591 | 174,353 | -3% | -$9,670 | ||||||
2019-05-20 | ADMP | Adamis Pharmaceuticals Corp | Moss Ronald B. | Chief Medical Officer | S - Sale | $1.77 | -8,741 | 276,255 | -3% | -$15,464 | ||||||
2019-05-20 | ADMP | Adamis Pharmaceuticals Corp | Marguglio David J. | SVP, Chief Business Officer | S - Sale | $1.77 | -8,735 | 387,583 | -2% | -$15,464 | ||||||
2019-05-20 | ADMP | Adamis Pharmaceuticals Corp | Hopkins Robert O | CFO | S - Sale | $1.73 | -7,559 | 340,348 | -2% | -$13,109 | ||||||
| M | 2019-05-20 | AGLE | Aeglea Biotherapeutics, Inc. | Quinn Anthony G. | Pres, CEO | P - Purchase | $6.77 | +26,592 | 321,738 | +9% | +$180,032 | |||||
| M | 2019-05-20 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.01 | +43,000 | 21,877,397 | 0% | +$472 | |||||
| M | 2019-05-20 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO | P - Purchase | $7.93 | +10,000 | 1,044,940 | +1% | +$79,326 | |||||
2019-05-20 | UROV | Urovant Sciences Ltd. | Dexxon Holdings Ltd. | 10% | P - Purchase | $8.05 | +10,000 | 45,448,839 | 0% | +$80,525 | ||||||
| DM | 2019-05-20 | MGNX | Macrogenics Inc | Risser Eric Blasius | SVP, Chief Business Officer | S - Sale+OE | $18.54 | -4,000 | 30,806 | -11% | -$74,157 | |||||
| M | 2019-05-20 | NVUS | Novus Therapeutics, Inc. | Turkel Catherine C. | Pres | S - Sale | $1.95 | -9,537 | 88,662 | -10% | -$18,612 | |||||
| M | 2019-05-20 | NVUS | Novus Therapeutics, Inc. | Kuwahara Jon | See Remarks | S - Sale | $1.95 | -5,276 | 5,974 | -47% | -$10,296 | |||||
| M | 2019-05-20 | NVUS | Novus Therapeutics, Inc. | Flesher Gregory J. | CEO | S - Sale | $1.95 | -14,638 | 156,918 | -9% | -$28,566 | |||||
2019-05-21 | BSTC | Biospecifics Technologies Corp | Wegman Toby | Dir, 10% | S - Sale | $64.06 | -5,500 | 945,073 | -1% | -$352,353 | ||||||
2019-05-21 | BSTC | Biospecifics Technologies Corp | Wegman Mark N | Dir | S - Sale | $64.04 | -6,000 | 74,272 | -7% | -$384,236 | ||||||
2019-05-21 | PRNB | Principia Biopharma Inc. | Orbimed Advisors LLC | 10% | S - Sale | $30.25 | -1,000,000 | 1,605,713 | -38% | -$30,250,000 | ||||||
2019-05-21 | BLPH | Bellerophon Therapeutics, Inc. | Wang Theodore T | Dir, 10% | P - Purchase | $0.61 | +43,280 | 506,979 | +9% | +$26,371 | ||||||
2019-05-21 | BLPH | Bellerophon Therapeutics, Inc. | Peacock Jonathan M | Dir | P - Purchase | $0.61 | +20,000 | 1,875,920 | +1% | +$12,198 | ||||||
2019-05-21 | BLPH | Bellerophon Therapeutics, Inc. | Tenenbaum Fabian | CEO | P - Purchase | $0.59 | +5,000 | 484,282 | +1% | +$2,975 | ||||||
2019-05-21 | SBPH | Spring Bank Pharmaceuticals, Inc. | Driscoll Martin J | Pres, CEO | P - Purchase | $6.63 | +5,000 | 75,400 | +7% | +$33,150 | ||||||
2019-05-20 | AKRX | Akorn Inc | Meyer Steven J | Dir | P - Purchase | $4.10 | +15,000 | 167,339 | +10% | +$61,500 | ||||||
2019-05-17 | BSTC | Biospecifics Technologies Corp | Chao Jennifer M | Dir | S - Sale | $63.72 | -4,000 | 1,313 | -75% | -$254,860 | ||||||
| D | 2019-05-17 | AMRN | Amarin Corp Plcuk | Stack David M | Dir | S - Sale+OE | $18.00 | -13,174 | 0 | -100% | -$237,139 | |||||
| D | 2019-05-20 | GWPH | Gw Pharmaceuticals Plc | Knappertz Volker | Chief Medical Officer | S - Sale+OE | $14.64 | -12,144 | 85,824 | -12% | -$177,846 | |||||
| D | 2019-05-20 | GWPH | Gw Pharmaceuticals Plc | Giacobello Scott M. | CFO | S - Sale+OE | $14.52 | -4,224 | 87,096 | -5% | -$61,332 | |||||
2019-05-20 | PLXP | Plx Pharma Inc. | Valentino Michael J | Exec COB | P - Purchase | $5.60 | +44,404 | 196,790 | +29% | +$248,662 | ||||||
2019-05-21 | APVO | Aptevo Therapeutics Inc. | Grant Grady III | Dir | P - Purchase | $0.80 | +10,000 | 10,000 | New | +$7,970 | ||||||
| D | 2018-01-29 | EYEN | Eyenovia, Inc. | Mario Ernest | Dir | P - Purchase | $10.00 | +90,000 | 236,770 | +61% | +$900,000 | |||||
| DM | 2019-05-17 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | S - Sale+OE | $15.35 | -217,515 | 1,211,455 | -15% | -$3,338,725 | |||||
2019-05-17 | NOVN | Novan, Inc. | Novak Andrew | VP, Accounting, Bus Ops | P - Purchase | $1.47 | +5,400 | 6,700 | +415% | +$7,938 | ||||||
2019-05-17 | NOVN | Novan, Inc. | Gay John M. | VP, Finance, Corp. Controller | P - Purchase | $1.50 | +14,900 | 15,000 | >999% | +$22,350 | ||||||
| M | 2019-05-17 | NOVN | Novan, Inc. | Stafford Paula B | Pres, COO | P - Purchase | $1.92 | +80,693 | 80,693 | New | +$154,633 | |||||
2019-05-17 | NOVN | Novan, Inc. | Martin G. Kelly | CEO | P - Purchase | $1.43 | +60,000 | 100,000 | +150% | +$85,800 | ||||||
| M | 2019-05-16 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $9.70 | +5,000 | 2,224,375 | 0% | +$48,492 | |||||
2019-05-17 | REPH | Recro Pharma, Inc. | Ajdler Arnaud | Dir | P - Purchase | $9.00 | +40,000 | 1,112,501 | +4% | +$360,000 | ||||||
| M | 2019-05-17 | NERV | Minerva Neurosciences, Inc. | Index Venture Associates III Ltd | 10% | S - Sale | $6.02 | -22,918 | 4,451,443 | -1% | -$137,896 | |||||
| D | 2019-05-15 | XYN | Xynomic Pharmaceuticals Holdings, Inc. | Xu Peixin | Former Dir. & 10% more owner | P - Purchase | $0.00 | +108,980 | 1,628,580 | +7% | +$0 | |||||
| D | 2019-05-15 | XYN | Xynomic Pharmaceuticals Holdings, Inc. | Bison Capital Holding Co Ltd | Former 10% more owner | P - Purchase | $0.00 | +108,980 | 1,628,580 | +7% | +$0 | |||||
| D | 2019-05-20 | TEVA | Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | EVP Global Operations | S - Sale+OE | $11.42 | -16,070 | 33,589 | -32% | -$183,519 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Viking Global Investors LP | 10% | P - Purchase | $7.54 | +21,608 | 0 | -100% | +$162,884 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Viking Global Performance LLC | 10% | P - Purchase | $7.54 | +21,608 | 0 | -100% | +$162,884 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Svf Investments (Uk) Ltd | 10% | P - Purchase | $7.54 | +21,607 | 22,725,277 | 0% | +$162,876 | |||||
2019-05-20 | APVO | Aptevo Therapeutics Inc. | White Marvin L | Pres, CEO | P - Purchase | $0.81 | +30,000 | 243,603 | +14% | +$24,300 | ||||||
| D | 2019-05-16 | MRTX | Mirati Therapeutics, Inc. | Donadio Jamie A | SVP, CFO | S - Sale+OE | $75.00 | -7,500 | 221 | -97% | -$562,500 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Lo Andrew | 10% | P - Purchase | $7.54 | +21,608 | 22,725,277 | 0% | +$162,884 | |||||
2019-05-16 | MTNB | Matinas Biopharma Holdings, Inc. | Stern Adam K | Dir | P - Purchase | $0.95 | +150,000 | 6,833,475 | +2% | +$142,500 | ||||||
2019-05-16 | MTNB | Matinas Biopharma Holdings, Inc. | Lepore Patrick G | Dir | P - Purchase | $0.95 | +100,000 | 100,000 | New | +$95,250 | ||||||
2019-05-16 | MTNB | Matinas Biopharma Holdings, Inc. | Conrad Herbert J | Dir | P - Purchase | $0.96 | +25,000 | 4,079,922 | +1% | +$24,115 | ||||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Qvt Associates Gp LLC | 10% | P - Purchase | $7.54 | +21,608 | 22,725,277 | 0% | +$162,884 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Machado Patrick | 10% | P - Purchase | $7.54 | +21,608 | 22,725,277 | 0% | +$162,884 | |||||
| M | 2019-05-16 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $5.18 | +10,000 | 36,958,570 | 0% | +$51,824 | |||||
| M | 2019-05-16 | TBPH | Theravance Biopharma, Inc. | O'Connor Donal | Dir | S - Sale | $20.46 | -4,000 | 27,571 | -13% | -$81,835 | |||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Roivant Sciences Ltd. | 10% | P - Purchase | $7.54 | +21,608 | 22,725,277 | 0% | +$162,884 | |||||
2019-05-16 | APLT | Applied Therapeutics Inc. | Shendelman Shoshana | Pres, CEO, 10% | P - Purchase | $10.00 | +125,000 | 4,876,379 | +3% | +$1,250,000 | ||||||
| D | 2019-05-16 | APLT | Applied Therapeutics Inc. | Marcus Joel S | Dir | P - Purchase | $10.00 | +150,000 | 404,860 | +59% | +$1,500,000 | |||||
| M | 2019-05-16 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $8.95 | -1,800 | 2,717,319 | 0% | -$16,105 | |||||
| D | 2019-05-17 | ZTS | Zoetis Inc. | David Glenn | CFO | S - Sale+OE | $102.22 | -8,191 | 10,549 | -44% | -$837,284 | |||||
2019-05-16 | BMY | Bristol Myers Squibb Co | Santiago Karen Murphy | Controller | S - Sale | $47.56 | -3,065 | 3,066 | -50% | -$145,771 | ||||||
2019-05-16 | BMY | Bristol Myers Squibb Co | Samuels Theodore R. II | Dir | P - Purchase | $47.29 | +5,000 | 27,000 | +23% | +$236,440 | ||||||
2019-05-20 | CMRX | Chimerix Inc | Sherman Michael A. | CEO | P - Purchase | $3.48 | +30,000 | 30,000 | New | +$104,316 | ||||||
2019-05-17 | ANIP | Ani Pharmaceuticals Inc | Marken James G. | SVP Ops, Prod Dev | S - Sale | $70.67 | -8,907 | 61,230 | -13% | -$629,458 | ||||||
2019-05-16 | FIXX | Homology Medicines, Inc. | 5Am Ventures Iv, L.P. | 10% | S - Sale | $21.47 | -615,000 | 221,435 | -74% | -$13,204,050 | ||||||
2019-05-16 | FIXX | Homology Medicines, Inc. | Parmar Kush | Dir, 10% | S - Sale | $21.47 | -615,000 | 221,435 | -74% | -$13,204,050 | ||||||
| M | 2019-05-16 | UROV | Urovant Sciences Ltd. | Dexxon Holdings Ltd. | 10% | P - Purchase | $7.10 | +11,608 | 45,424,354 | 0% | +$82,359 | |||||
2019-05-16 | MRNS | Marinus Pharmaceuticals Inc | Smith Edward F | CFO | S - Sale | $5.03 | -24,211 | 20,097 | -55% | -$121,781 | ||||||
2019-05-17 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | White Barbara | Chief Medical Officer | P - Purchase | $7.20 | +1,389 | 185,548 | +1% | +$10,001 | ||||||
| D | 2019-05-16 | TEVA | Teva Pharmaceutical Industries Ltd | De Notaristefani Carlo | EVP Global Operations | S - Sale+OE | $11.76 | -629 | 18,784 | -3% | -$7,397 | |||||
2019-05-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.08 | +50,000 | 215,891,633 | 0% | +$103,931 | ||||||
2019-05-14 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $14.27 | -25,817 | 729,879 | -3% | -$368,409 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Thomsen Jillian B. | SVP, Chief Accounting Officer | S - Sale | $31.37 | -1,928 | 164,463 | -1% | -$60,481 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $31.37 | -13,383 | 295,736 | -4% | -$419,825 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Nicholson John | SVP, COO | S - Sale | $31.37 | -4,077 | 166,578 | -2% | -$127,895 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, CFO | S - Sale | $31.37 | -3,767 | 127,935 | -3% | -$118,171 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Hora Maninder | SVP Pharma Dev, Mfg Ops | S - Sale | $31.37 | -2,449 | 94,694 | -3% | -$76,825 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Doberstein Stephen K | SVP, Chief Scientific Officer | S - Sale | $31.37 | -3,461 | 95,913 | -3% | -$108,572 | ||||||
| D | 2019-05-15 | GWPH | Gw Pharmaceuticals Plc | Tovey Christopher J. | COO | S - Sale+OE | $15.01 | -1,200 | 2,503 | -32% | -$18,012 | |||||
| M | 2019-05-15 | FTSV | Forty Seven, Inc. | Majeti Ravindra | Dir | S - Sale | $16.02 | -4,311 | 1,421,400 | 0% | -$69,044 | |||||
2019-05-16 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $8.53 | -22,702 | 449,217 | -5% | -$193,755 | ||||||
| M | 2019-02-15 | AGLE | Aeglea Biotherapeutics, Inc. | Quinn Anthony G. | Pres, CEO | P - Purchase | $6.75 | +18,713 | 295,146 | +7% | +$126,399 | |||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, CRO | S - Sale | $165.41 | -61 | 53,262 | 0% | -$10,090 | ||||||
| M | 2019-05-13 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.01 | +81,500 | 21,834,397 | 0% | +$1,037 | |||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Controller | S - Sale | $165.41 | -161 | 17,928 | -1% | -$26,631 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale | $165.41 | -83 | 35,003 | 0% | -$13,729 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | EVP, CMO | S - Sale | $165.41 | -241 | 13,736 | -2% | -$39,864 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP\Chief Commercial Officer | S - Sale | $165.41 | -133 | 33,380 | 0% | -$22,000 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Global Research, CSO | S - Sale | $165.41 | -91 | 31,553 | 0% | -$15,052 | ||||||
| D | 2019-05-15 | ALNY | Alnylam Pharmaceuticals, Inc. | Maraganore John | CEO | S - Sale+OE | $70.00 | -49,457 | 193,092 | -20% | -$3,461,990 | |||||
2019-05-15 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale | $12.84 | -25,000 | 182,069 | -12% | -$321,042 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |